Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03542838
Other study ID # PTVA OA-001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 12, 2018
Est. completion date February 11, 2021

Study information

Verified date March 2021
Source Sorrento Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the safety of resiniferatoxin in patients with moderate to severe knee pain due to osteoarthritis.


Description:

This study is to evaluate the safety of resiniferatoxin administered intra-articularly to subjects with moderate to severe knee pain due to osteoarthritis (OA). It is also to assess the preliminary efficacy of resiniferatoxin to relieve knee pain when walking.


Recruitment information / eligibility

Status Completed
Enrollment 94
Est. completion date February 11, 2021
Est. primary completion date April 13, 2020
Accepts healthy volunteers No
Gender All
Age group 35 Years to 85 Years
Eligibility Inclusion criteria: 1. Age: 35 years to 85 years 2. Diagnosis of moderate to severe pain due to OA: Moderate to severe osteoarthritis, based on American College of Rheumatology (ACR) criteria 3. BMI < 45 kg/m2 4. Pain in the target knee has been treated with at least 2 analgesic agents, including at least one NSAID 5. Prior failure in at least two prior analgesic agents (at least one NSAID) 6. Willing to abstain from other intra-articular treatments of the knee or any knee surgery for at least 24 weeks after treatment 7. Ability to comply with the study and give informed consent 8. If on an opioid medication, stable dose for at least 4 weeks prior to injection with no increase in dose leading up to study injection 9. If on NSAIDs, be on a stable analgesic regimen for at least 4 weeks prior to injection 10. If on pain regimens other than opioid medication or NSAIDs, be on a stable regimen for at least 30 days 11. Is in good general health and is considered to have a physical status that is American Society of Anesthesiologists (ASA) category = 3 12. Able to comply with study procedures, including the recording of daily questionnaires Exclusion Criteria: 1. Has evidence or history of a coagulopathy or hemostasis problem at Screening or Baseline (Day 1) 2. Treatment knee injections with corticosteroids within 30 days or hyaluronic acid within 3 months prior to the procedure 3. If on opioid analgesics, an upper limit of 30 mg/day of oral morphine sulfate, 20 mg/day of oxycodone, 30 mg/day of hydrocodone, or 300 mg/day of tramadol, or equivalent 4. Any of the following lab abnormalities within one week of the treatment day: - Platelet count <100,000 cells/mm3 - Total neutrophil count <1500 cells/mm3 - Serum creatinine = 1.5 x ULN - Alanine aminotransferase (ALT) > 3.0 x ULN - Aspartate aminotransferase (AST) > 3.0 x ULN - Alkaline phosphatase > 2.0 ULN - Bilirubin > 1.5 x ULN - INR > 1.5 x ULN - Temperature = 100.4°F or other evidence of an infection 5. Concurrent use of opioids for indications other than knee pain 6. History of substance abuse 7. Has an allergy or hypersensitivity to chili peppers, capsaicin, resiniferatoxin or radiographic contrast agents 8. Female subjects who are pregnant at Screening or are planning on becoming pregnant, or are currently breastfeeding 9. Subjects with any medical condition or comorbidities that could adversely impact study participation or safety, conduct of the study, or interfere with pain assessments 10. Subjects who have participated in a clinical study of an investigational drug within 4 half-lives of Screening or are scheduled to receive and investigational agent while participating in this study 11. Sensory peripheral neuropathy that is CTCAE Grade 2 or higher at Screening 12. Arterial or venous thrombi, myocardial infarction, admission for unstable angina, cardiac angioplasty, or stenting within 12 months prior to Screening 13. Evidence or history of any hemorrhage or bleeding event that is higher than CTCAE Grade 1 within 4 weeks prior to injection. 14. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C. Positive tests for HIV-1 or -2 antibodies, hepatitis B surface antigen, or hepatitis C antibodies. 15. Concurrent medical or arthritic conditions that could interfere with evaluation of the index knee joint including fibromyalgia, rheumatoid arthritis, or other inflammatory arthropathies affecting the knee joint 16. Subjects with significant pain in other joints may be excluded at the discretion of the investigator 17. Subject has undergone arthroscopic or open surgery to the knee within 6 months of the planned injection day 18. Subject has undergone replacement surgery of the treatment knee 19. Presence of surgical hardware or other foreign bodies in the treatment knee

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Resiniferatoxin
Resiniferatoxin is a compound purified from natural sources.
Saline
Saline is a normal physiological solution

Locations

Country Name City State
United States Brigham & Women's Hospital Boston Massachusetts
United States Hermann Drive Surgical Hospital Houston Texas
United States Snibbe Orthopedics Los Angeles California
United States University of Miami/Sylvester Comprehensive Cancer Center Miami Florida

Sponsors (1)

Lead Sponsor Collaborator
Sorrento Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety measurement Incidence and severity of adverse events baseline through week 52
Secondary Improvement of knee pain when walking Improvement in pain score versus baseline using the WOMAC Osteoarthritis Index question A1 (pain on walking, 11-point numerical rating scale) baseline through week 52
See also
  Status Clinical Trial Phase
Recruiting NCT03895489 - Effectiveness of the Journey Total Knee Arthroplasty Versus Two Standard of Care Total Knee Arthroplasty Prostheses N/A
Completed NCT03660943 - A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain Phase 3
Completed NCT04531969 - Comparison of Outpatient and Inpatient Spa Therapy N/A
Completed NCT02848027 - Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment Phase 3
Completed NCT05160246 - The Instant Effect of Kinesiology Taping in Patients With Knee OA N/A
Recruiting NCT06080763 - Biomechanics and Clinical Outcomes in Responders and Non-Responders
Completed NCT03643588 - The Comparison of HYAJOINT Plus and Hyalgan Hyaluronan Supplement for Knee Osteoarthritis Pain N/A
Active, not recruiting NCT05100225 - Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis Phase 2
Active, not recruiting NCT04061733 - New Hydroxyethyl Cellulose Hydrogel for the Treatment of the Pain of Knee Arthrosis N/A
Completed NCT04051489 - A Novel Smartphone Application for "Smart" Knee Osteoarthritis Trials
Recruiting NCT05546541 - Epidemiology and Nutrition
Recruiting NCT05447767 - Prediction AlgoriThm for regeneraTive Medicine Approach in knEe OA: New Decision-making Process Based on Patient pRofiliNg Phase 2
Not yet recruiting NCT04448106 - Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis Phase 2
Not yet recruiting NCT03225911 - Effect of a Lateral Wedge Insole and Simple Knee Sleeve in Individuals With Knee Osteoarthritis N/A
Completed NCT05070871 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women N/A
Completed NCT05703087 - Positive Cueing in Knee Arthroplasty. N/A
Not yet recruiting NCT06042426 - Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population Phase 4
Not yet recruiting NCT02854176 - Somatosensory Stimulation in Knee Osteoarthritis Phase 2
Terminated NCT02615522 - Prospective Post Market Clinical Follow-Up of the Primary Knee Endoprosthesis BPK-S Integration
Terminated NCT02909257 - Motor-Sparing Femoral Nerve Block Dose Phase 4